SNO 2019: PD-1 Inhibition Can Be Combined With Interleukin-12 in Patients With Recurrent Glioblastoma
Initial results with this rational combination are consistent with immune-mediated antitumor effects and favorable safety.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.